DCT

1:26-cv-00305

Veloxis Pharma Inc v. Glenmark Pharma Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00305, D. Del., 03/20/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because the defendant, Glenmark Pharmaceuticals Inc., USA, is incorporated in Delaware and therefore resides in the district.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market generic extended-release tacrolimus tablets constitutes an act of infringement of a patent covering stabilized formulations of the drug.
  • Technical Context: The technology concerns pharmaceutical formulations for tacrolimus, an immunosuppressant drug widely used to prevent organ rejection in transplant patients, that improve its stability and control the formation of degradation products.
  • Key Procedural History: This action arises under the Hatch-Waxman Act, triggered by Defendant's filing of ANDA No. 217905, which seeks FDA approval to market a generic version of Plaintiff's drug, ENVARSUS XR®, before the expiration of the patent-in-suit. The filing included a Paragraph IV Certification asserting that the patent is not infringed and/or is invalid.

Case Timeline

Date Event
2008-07-08 '095 Patent Priority Date
2025-09-02 '095 Patent Issue Date
2026-02-06 Date of Defendant's ANDA Notice Letter
2026-02-07 Date Plaintiff received Defendant's Notice Letter
2026-03-20 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

  • Patent Identification: U.S. Patent No. 12,403,095 ("the '095 Patent"), "Stabilized Tacrolimus Composition," issued September 2, 2025.

The Invention Explained

  • Problem Addressed: The patent's background section describes that tacrolimus, a potent but poorly soluble immunosuppressant, is susceptible to chemical degradation when formulated '095 Patent, col. 2:48-59 This formation of impurities, such as 8-epitacrolimus, is "highly undesirable" and subject to strict regulatory limits, creating a challenge for developing stable, effective oral dosage forms '095 Patent, col. 2:6-14 '095 Patent, col. 4:58-62
  • The Patented Solution: The invention claims to solve this problem by creating a pharmaceutical composition that includes a "stabilizing agent" along with the tacrolimus in a vehicle '095 Patent, abstract This stabilizing agent, which is also a metal chelating agent such as an organic acid, provides a pH below 7 in the composition, which is asserted to prevent or reduce the formation of the 8-epitacrolimus degradation product upon storage '095 Patent, col. 3:15-34 '095 Patent, col. 4:6-14
  • Technical Importance: This approach allows for the creation of solid dispersion formulations of tacrolimus that can improve bioavailability while maintaining chemical stability over the product's shelf-life, thereby meeting regulatory requirements for purity '095 Patent, col. 2:50-59

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶33
  • Essential elements of independent claim 1 include:
    • A pharmaceutical composition comprising a solid dispersion of tacrolimus in a mixture of a vehicle and a stabilizing agent.
    • The stabilizing agent is a metal chelating agent.
    • The stabilizing agent provides a pH below 7 in the composition.
    • The composition comprises from about 0.5 to about 5% of tacrolimus.
    • The composition contains no more than 0.5% more 8-epitacrolimus after storage at 40° C. at 75% relative humidity for 5 weeks compared to prior to storage.
    • The tacrolimus is the sole active ingredient.
    • The vehicle does not include a cyclo-dextrin.
  • The complaint does not explicitly reserve the right to assert dependent claims, though this is common practice.

III. The Accused Instrumentality

Product Identification

  • Defendant's proposed 0.75 mg, 1 mg, and 4 mg extended-release tablets of tacrolimus, which are the subject of ANDA No. 217905 ("Defendant's ANDA Products") Compl. ¶1

Functionality and Market Context

  • The complaint alleges that the Defendant's ANDA Products are generic versions of Plaintiff's brand name drug, ENVARSUS XR® Compl. ¶2 By filing its ANDA, Defendant has represented to the FDA that its products have the same active ingredient, dosage form, strengths, and route of administration as ENVARSUS XR®, and that they are bioequivalent Compl. ¶23 ENVARSUS XR® is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients Compl. ¶19 The core of the infringement allegation is that to be a bioequivalent generic of a product covered by the '095 Patent, the ANDA product must necessarily possess the claimed features.

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that the Defendant's ANDA Products, to be bioequivalent to ENVARSUS XR®, must satisfy each element of at least claim 1 of the '095 Patent Compl. ¶34 The specific details of the accused product's formulation are not public and are contained within the confidential ANDA submission. The following chart summarizes the infringement allegations as inferred from the complaint's theory of bioequivalence.

'095 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising a solid dispersion of tacrolimus in a mixture of a vehicle and a stabilizing agent... Defendant's ANDA Products are alleged to be a pharmaceutical composition comprising a solid dispersion of tacrolimus with a vehicle and stabilizing agent. ¶34 col. 7:56-62
...that is a metal chelating agent... The stabilizing agent in the ANDA product is alleged to be a metal chelating agent. ¶34 col. 8:7-9
...and provides a pH below 7 in the composition... The ANDA product is alleged to provide a pH below 7 when re-dispersed in water. ¶34 col. 7:26-31
...the composition comprises from about 0.5 to about 5% of tacrolimus... The ANDA product is alleged to contain tacrolimus within the claimed percentage range. ¶34 col. 15:60-63
...the composition contains no more than 0.5% more 8-epitacrolimus after storage at 40° C. at 75% relative humidity for 5 weeks... The ANDA product is alleged to meet the claimed stability requirement regarding the formation of the 8-epitacrolimus degradant. ¶34 col. 15:63-66
...the tacrolimus is the sole active ingredient in the composition... The ANDA product is alleged to contain tacrolimus as its only active pharmaceutical ingredient. ¶34 col. 16:1-3
...and (iv) the vehicle does not include a cyclo-dextrin. The ANDA product's vehicle is alleged to not contain a cyclo-dextrin. ¶34 col. 16:3-4
  • Identified Points of Contention:
    • Factual Question: A primary point of contention will be entirely factual and dependent on the contents of the confidential ANDA. The key question is whether Defendant's formulation, in fact, contains a "stabilizing agent that is a metal chelating agent" and whether its stability data shows formation of 8-epitacrolimus within the claimed limits.
    • Scope Questions: The dispute may raise questions about the scope of "stabilizing agent." For example, if the Defendant's formulation contains an acidic excipient that is not one of the specific examples in the patent (e.g., tartaric or citric acid), a dispute may arise as to whether that excipient qualifies as a "metal chelating agent" within the meaning of the claim.

V. Key Claim Terms for Construction

  • The Term: "stabilizing agent that is a metal chelating agent"

    • Context and Importance: This term is central to the inventive concept of achieving stability. The infringement analysis will depend on whether an excipient in Defendant's formulation falls within the definition of this term. Practitioners may focus on this term because it combines a functional property ("stabilizing") with a structural/chemical one ("metal chelating agent").
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent defines a "stabilizing agent" functionally as being "capable of providing a pH below 7" '095 Patent, col. 3:20-22 It also provides a list of suitable organic acids, implying the term is not limited to a closed set '095 Patent, col. 8:39-44 This could support an interpretation covering any acidic compound with some metal-binding capability.
      • Evidence for a Narrower Interpretation: The specification states the agent is "preferably a metal chelating agent" and specifically highlights "citric acid, tartaric acid, oxalic acid" as effective examples '095 Patent, col. 8:8-12 A party could argue that the term requires a significant and intended chelating function, not merely incidental properties, potentially narrowing the scope to agents known primarily for chelation.

  • The Term: "solid dispersion"

    • Context and Importance: The claim requires tacrolimus to be in a "solid dispersion." How Defendant's product is manufactured and the physical state of the drug in the final tablet could be a point of contention.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent provides a broad definition: "a drug substance or an active ingredient dispersed or dissolved in an inert vehicle, carrier, diluent or matrix in solid state," explicitly including a "solid solution" '095 Patent, col. 7:56-62 This suggests the term covers a range of physical states, not just a molecular dispersion.
      • Evidence for a Narrower Interpretation: The examples in the patent describe a melt-spray-congeal process where tacrolimus is dissolved in a melted vehicle '095 Patent, col. 15:35-46 A party might argue that this process, which results in a molecular-level dispersion, implicitly defines the required characteristics of a "solid dispersion" and that other formulation methods (e.g., simple blending of fine particles) do not qualify.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. The inducement allegation is based on the claim that Defendant will, upon approval, encourage infringement through its marketing and product labeling with knowledge of the '095 Patent Compl. ¶37 The contributory infringement allegation is based on the assertion that Defendant's ANDA Products are especially adapted for an infringing use and have no substantial non-infringing use Compl. ¶38
  • Willful Infringement: The complaint alleges that Defendant had knowledge of the '095 Patent prior to filing its ANDA and that the case is "exceptional," which forms the basis for a willfulness claim and a request for attorneys' fees Compl. ¶41 Compl. ¶42 The pre-suit knowledge is inherent in the ANDA process, which requires the filer to address listed patents.

VII. Analyst's Conclusion: Key Questions for the Case

This Hatch-Waxman litigation will likely center on the confidential details of the defendant's generic formulation. The key questions for the court are:

  • A core issue will be one of formulation identity: Does the formulation described in Glenmark's confidential ANDA, in fact, contain an excipient that functions as a "stabilizing agent that is a metal chelating agent" and provide a pH below 7, or does it achieve stability through a different, non-infringing mechanism?
  • A second pivotal question will be evidentiary and factual: Does the stability data for Glenmark's product demonstrate the formation of 8-epitacrolimus at a rate that falls outside the limitation of "no more than 0.5% more" after 5 weeks under the specified storage conditions, as claimed in Claim 1?
  • Finally, the case may involve a question of definitional scope: If Glenmark's formulation uses an acidic excipient not explicitly listed in the patent's preferred embodiments, the court will have to determine whether that substance meets the claim-construed definition of a "metal chelating agent."
Loading Complaint